Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey
Identifieur interne : 000016 ( PascalFrancis/Corpus ); précédent : 000015; suivant : 000017Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey
Auteurs : Elizabeth Stringer ; John Bohnsack ; Suzanne L. Bowyer ; Thomas A. Griffin ; Adam M. Huber ; Bianca Lang ; Carol B. Lindsley ; Sylvia Ota ; Clarissa Pilkington ; Ann M. Reed ; Rosie Scuccimarri ; Brian M. FeldmanSource :
- Journal of rheumatology [ 0315-162X ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Objective. There are a number of different approaches to the initial treatment of juvenile dermatomyositis (JDM). We assessed the therapeutic approaches of North American pediatric rheumatologists to inform future studies of therapy in JDM. Methods. A survey describing clinical cases of JDM was sent to pediatric rheumatologists. The cases described children with varying severity of typical disease, disease with atypical features, or refractory disease. Three open-ended questions were asked following each case: (1) What additional investigations would you order; (2) What medicine(s) would you start (dose, route, frequency, adjustment over time); and (3) What nonmedication treatment(s) would you start. Results. The response rate was 84% (141/167). For typical cases of JDM, regardless of severity, almost all respondents used corticosteroids and another medication, methotrexate (MTX) being the most commonly used. The route and pattern of corticosteroid administration was variable. Intravenous immunoglobulin (IVIG) was used more frequently for more severe disease, for refractory disease, and for prominent cutaneous disease. Hydroxychloroquine was often used in milder cases and cases principally characterized by rash. Cyclophosphamide was reserved for ulcerative disease and JDM complicated by lung disease. Conclusion. For the majority of North American pediatric rheumatologists, corticosteroids and MTX appear to be the standard of care for typical cases of JDM. There is variability, however, in the route of administration of corticosteroids and use of IVIG and hydroxychloroquine.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 10-0446161 INIST |
---|---|
ET : | Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey |
AU : | STRINGER (Elizabeth); BOHNSACK (John); BOWYER (Suzanne L.); GRIFFIN (Thomas A.); HUBER (Adam M.); LANG (Bianca); LINDSLEY (Carol B.); OTA (Sylvia); PILKINGTON (Clarissa); REED (Ann M.); SCUCCIMARRI (Rosie); FELDMAN (Brian M.) |
AF : | IWK Health Centre/Halifax, Nova Scotia/Canada; University of Utah School of Medicine/Salt Lake City, Utah/Etats-Unis; Indiana University School of Medicine/Indianapolis, Indiana/Etats-Unis; Cincinnati Children's Hospital/Cincinnati, Ohio/Etats-Unis; University of Kansas Medical Center/Kansas City, Kansas/Etats-Unis; The Hospital for Sick Children/Toronto, Ontario/Canada; Great Ormond Street Hospital for Children/London/Royaume-Uni; Mayo Clinic/Rochester, Minnesota/Etats-Unis; Montreal Children's Hospital/Montreal, Quebec/Canada |
DT : | Publication en série; Niveau analytique |
SO : | Journal of rheumatology; ISSN 0315-162X; Coden JRHUA9; Canada; Da. 2010; Vol. 37; No. 9; Pp. 1953-1961; Bibl. 43 ref. |
LA : | Anglais |
EA : | Objective. There are a number of different approaches to the initial treatment of juvenile dermatomyositis (JDM). We assessed the therapeutic approaches of North American pediatric rheumatologists to inform future studies of therapy in JDM. Methods. A survey describing clinical cases of JDM was sent to pediatric rheumatologists. The cases described children with varying severity of typical disease, disease with atypical features, or refractory disease. Three open-ended questions were asked following each case: (1) What additional investigations would you order; (2) What medicine(s) would you start (dose, route, frequency, adjustment over time); and (3) What nonmedication treatment(s) would you start. Results. The response rate was 84% (141/167). For typical cases of JDM, regardless of severity, almost all respondents used corticosteroids and another medication, methotrexate (MTX) being the most commonly used. The route and pattern of corticosteroid administration was variable. Intravenous immunoglobulin (IVIG) was used more frequently for more severe disease, for refractory disease, and for prominent cutaneous disease. Hydroxychloroquine was often used in milder cases and cases principally characterized by rash. Cyclophosphamide was reserved for ulcerative disease and JDM complicated by lung disease. Conclusion. For the majority of North American pediatric rheumatologists, corticosteroids and MTX appear to be the standard of care for typical cases of JDM. There is variability, however, in the route of administration of corticosteroids and use of IVIG and hydroxychloroquine. |
CC : | 002B15I; 002B07; 002B17H |
FD : | Traitement; Voie abord; Dermatomyosite; Adolescent; Amérique du Nord; Enfant; Arthrite; Rhumatologie; Enquête; Pédiatrie; Myosite |
FG : | Homme; Amérique; Maladie autoimmune; Maladie de système; Pathologie du muscle strié; Pathologie de la peau; Pathologie du tissu conjonctif; Immunopathologie; Pathologie du système ostéoarticulaire |
ED : | Treatment; Surgical approach; Dermatomyositis; Adolescent; North America; Child; Arthritis; Rheumatology; Survey; Pediatrics; Myositis |
EG : | Human; America; Autoimmune disease; Systemic disease; Striated muscle disease; Skin disease; Connective tissue disease; Immunopathology; Diseases of the osteoarticular system |
SD : | Tratamiento; Vía abordaje; Dermatomiositis; Adolescente; America del norte; Niño; Artritis; Reumatología; Encuesta; Pediatría; Miositis |
LO : | INIST-16024.354000194840140270 |
ID : | 10-0446161 |
Links to Exploration step
Pascal:10-0446161Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey</title>
<author><name sortKey="Stringer, Elizabeth" sort="Stringer, Elizabeth" uniqKey="Stringer E" first="Elizabeth" last="Stringer">Elizabeth Stringer</name>
<affiliation><inist:fA14 i1="01"><s1>IWK Health Centre</s1>
<s2>Halifax, Nova Scotia</s2>
<s3>CAN</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>University of Utah School of Medicine</s1>
<s2>Salt Lake City, Utah</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Indiana University School of Medicine</s1>
<s2>Indianapolis, Indiana</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Cincinnati Children's Hospital</s1>
<s2>Cincinnati, Ohio</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>The Hospital for Sick Children</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>Great Ormond Street Hospital for Children</s1>
<s2>London</s2>
<s3>GBR</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="08"><s1>Mayo Clinic</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="09"><s1>Montreal Children's Hospital</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bohnsack, John" sort="Bohnsack, John" uniqKey="Bohnsack J" first="John" last="Bohnsack">John Bohnsack</name>
</author>
<author><name sortKey="Bowyer, Suzanne L" sort="Bowyer, Suzanne L" uniqKey="Bowyer S" first="Suzanne L." last="Bowyer">Suzanne L. Bowyer</name>
</author>
<author><name sortKey="Griffin, Thomas A" sort="Griffin, Thomas A" uniqKey="Griffin T" first="Thomas A." last="Griffin">Thomas A. Griffin</name>
</author>
<author><name sortKey="Huber, Adam M" sort="Huber, Adam M" uniqKey="Huber A" first="Adam M." last="Huber">Adam M. Huber</name>
</author>
<author><name sortKey="Lang, Bianca" sort="Lang, Bianca" uniqKey="Lang B" first="Bianca" last="Lang">Bianca Lang</name>
</author>
<author><name sortKey="Lindsley, Carol B" sort="Lindsley, Carol B" uniqKey="Lindsley C" first="Carol B." last="Lindsley">Carol B. Lindsley</name>
</author>
<author><name sortKey="Ota, Sylvia" sort="Ota, Sylvia" uniqKey="Ota S" first="Sylvia" last="Ota">Sylvia Ota</name>
</author>
<author><name sortKey="Pilkington, Clarissa" sort="Pilkington, Clarissa" uniqKey="Pilkington C" first="Clarissa" last="Pilkington">Clarissa Pilkington</name>
</author>
<author><name sortKey="Reed, Ann M" sort="Reed, Ann M" uniqKey="Reed A" first="Ann M." last="Reed">Ann M. Reed</name>
</author>
<author><name sortKey="Scuccimarri, Rosie" sort="Scuccimarri, Rosie" uniqKey="Scuccimarri R" first="Rosie" last="Scuccimarri">Rosie Scuccimarri</name>
</author>
<author><name sortKey="Feldman, Brian M" sort="Feldman, Brian M" uniqKey="Feldman B" first="Brian M." last="Feldman">Brian M. Feldman</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0446161</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0446161 INIST</idno>
<idno type="RBID">Pascal:10-0446161</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000016</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey</title>
<author><name sortKey="Stringer, Elizabeth" sort="Stringer, Elizabeth" uniqKey="Stringer E" first="Elizabeth" last="Stringer">Elizabeth Stringer</name>
<affiliation><inist:fA14 i1="01"><s1>IWK Health Centre</s1>
<s2>Halifax, Nova Scotia</s2>
<s3>CAN</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>University of Utah School of Medicine</s1>
<s2>Salt Lake City, Utah</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Indiana University School of Medicine</s1>
<s2>Indianapolis, Indiana</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Cincinnati Children's Hospital</s1>
<s2>Cincinnati, Ohio</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>The Hospital for Sick Children</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="07"><s1>Great Ormond Street Hospital for Children</s1>
<s2>London</s2>
<s3>GBR</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="08"><s1>Mayo Clinic</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="09"><s1>Montreal Children's Hospital</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bohnsack, John" sort="Bohnsack, John" uniqKey="Bohnsack J" first="John" last="Bohnsack">John Bohnsack</name>
</author>
<author><name sortKey="Bowyer, Suzanne L" sort="Bowyer, Suzanne L" uniqKey="Bowyer S" first="Suzanne L." last="Bowyer">Suzanne L. Bowyer</name>
</author>
<author><name sortKey="Griffin, Thomas A" sort="Griffin, Thomas A" uniqKey="Griffin T" first="Thomas A." last="Griffin">Thomas A. Griffin</name>
</author>
<author><name sortKey="Huber, Adam M" sort="Huber, Adam M" uniqKey="Huber A" first="Adam M." last="Huber">Adam M. Huber</name>
</author>
<author><name sortKey="Lang, Bianca" sort="Lang, Bianca" uniqKey="Lang B" first="Bianca" last="Lang">Bianca Lang</name>
</author>
<author><name sortKey="Lindsley, Carol B" sort="Lindsley, Carol B" uniqKey="Lindsley C" first="Carol B." last="Lindsley">Carol B. Lindsley</name>
</author>
<author><name sortKey="Ota, Sylvia" sort="Ota, Sylvia" uniqKey="Ota S" first="Sylvia" last="Ota">Sylvia Ota</name>
</author>
<author><name sortKey="Pilkington, Clarissa" sort="Pilkington, Clarissa" uniqKey="Pilkington C" first="Clarissa" last="Pilkington">Clarissa Pilkington</name>
</author>
<author><name sortKey="Reed, Ann M" sort="Reed, Ann M" uniqKey="Reed A" first="Ann M." last="Reed">Ann M. Reed</name>
</author>
<author><name sortKey="Scuccimarri, Rosie" sort="Scuccimarri, Rosie" uniqKey="Scuccimarri R" first="Rosie" last="Scuccimarri">Rosie Scuccimarri</name>
</author>
<author><name sortKey="Feldman, Brian M" sort="Feldman, Brian M" uniqKey="Feldman B" first="Brian M." last="Feldman">Brian M. Feldman</name>
</author>
</analytic>
<series><title level="j" type="main">Journal of rheumatology</title>
<title level="j" type="abbreviated">J. rheumatol.</title>
<idno type="ISSN">0315-162X</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of rheumatology</title>
<title level="j" type="abbreviated">J. rheumatol.</title>
<idno type="ISSN">0315-162X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Arthritis</term>
<term>Child</term>
<term>Dermatomyositis</term>
<term>Myositis</term>
<term>North America</term>
<term>Pediatrics</term>
<term>Rheumatology</term>
<term>Surgical approach</term>
<term>Survey</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Traitement</term>
<term>Voie abord</term>
<term>Dermatomyosite</term>
<term>Adolescent</term>
<term>Amérique du Nord</term>
<term>Enfant</term>
<term>Arthrite</term>
<term>Rhumatologie</term>
<term>Enquête</term>
<term>Pédiatrie</term>
<term>Myosite</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective. There are a number of different approaches to the initial treatment of juvenile dermatomyositis (JDM). We assessed the therapeutic approaches of North American pediatric rheumatologists to inform future studies of therapy in JDM. Methods. A survey describing clinical cases of JDM was sent to pediatric rheumatologists. The cases described children with varying severity of typical disease, disease with atypical features, or refractory disease. Three open-ended questions were asked following each case: (1) What additional investigations would you order; (2) What medicine(s) would you start (dose, route, frequency, adjustment over time); and (3) What nonmedication treatment(s) would you start. Results. The response rate was 84% (141/167). For typical cases of JDM, regardless of severity, almost all respondents used corticosteroids and another medication, methotrexate (MTX) being the most commonly used. The route and pattern of corticosteroid administration was variable. Intravenous immunoglobulin (IVIG) was used more frequently for more severe disease, for refractory disease, and for prominent cutaneous disease. Hydroxychloroquine was often used in milder cases and cases principally characterized by rash. Cyclophosphamide was reserved for ulcerative disease and JDM complicated by lung disease. Conclusion. For the majority of North American pediatric rheumatologists, corticosteroids and MTX appear to be the standard of care for typical cases of JDM. There is variability, however, in the route of administration of corticosteroids and use of IVIG and hydroxychloroquine.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0315-162X</s0>
</fA01>
<fA02 i1="01"><s0>JRHUA9</s0>
</fA02>
<fA03 i2="1"><s0>J. rheumatol.</s0>
</fA03>
<fA05><s2>37</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>STRINGER (Elizabeth)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BOHNSACK (John)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BOWYER (Suzanne L.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GRIFFIN (Thomas A.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HUBER (Adam M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>LANG (Bianca)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LINDSLEY (Carol B.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>OTA (Sylvia)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>PILKINGTON (Clarissa)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>REED (Ann M.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>SCUCCIMARRI (Rosie)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>FELDMAN (Brian M.)</s1>
</fA11>
<fA14 i1="01"><s1>IWK Health Centre</s1>
<s2>Halifax, Nova Scotia</s2>
<s3>CAN</s3>
</fA14>
<fA14 i1="02"><s1>University of Utah School of Medicine</s1>
<s2>Salt Lake City, Utah</s2>
<s3>USA</s3>
</fA14>
<fA14 i1="03"><s1>Indiana University School of Medicine</s1>
<s2>Indianapolis, Indiana</s2>
<s3>USA</s3>
</fA14>
<fA14 i1="04"><s1>Cincinnati Children's Hospital</s1>
<s2>Cincinnati, Ohio</s2>
<s3>USA</s3>
</fA14>
<fA14 i1="05"><s1>University of Kansas Medical Center</s1>
<s2>Kansas City, Kansas</s2>
<s3>USA</s3>
</fA14>
<fA14 i1="06"><s1>The Hospital for Sick Children</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
</fA14>
<fA14 i1="07"><s1>Great Ormond Street Hospital for Children</s1>
<s2>London</s2>
<s3>GBR</s3>
</fA14>
<fA14 i1="08"><s1>Mayo Clinic</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
</fA14>
<fA14 i1="09"><s1>Montreal Children's Hospital</s1>
<s2>Montreal, Quebec</s2>
<s3>CAN</s3>
</fA14>
<fA20><s1>1953-1961</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16024</s2>
<s5>354000194840140270</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>43 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0446161</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of rheumatology</s0>
</fA64>
<fA66 i1="01"><s0>CAN</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objective. There are a number of different approaches to the initial treatment of juvenile dermatomyositis (JDM). We assessed the therapeutic approaches of North American pediatric rheumatologists to inform future studies of therapy in JDM. Methods. A survey describing clinical cases of JDM was sent to pediatric rheumatologists. The cases described children with varying severity of typical disease, disease with atypical features, or refractory disease. Three open-ended questions were asked following each case: (1) What additional investigations would you order; (2) What medicine(s) would you start (dose, route, frequency, adjustment over time); and (3) What nonmedication treatment(s) would you start. Results. The response rate was 84% (141/167). For typical cases of JDM, regardless of severity, almost all respondents used corticosteroids and another medication, methotrexate (MTX) being the most commonly used. The route and pattern of corticosteroid administration was variable. Intravenous immunoglobulin (IVIG) was used more frequently for more severe disease, for refractory disease, and for prominent cutaneous disease. Hydroxychloroquine was often used in milder cases and cases principally characterized by rash. Cyclophosphamide was reserved for ulcerative disease and JDM complicated by lung disease. Conclusion. For the majority of North American pediatric rheumatologists, corticosteroids and MTX appear to be the standard of care for typical cases of JDM. There is variability, however, in the route of administration of corticosteroids and use of IVIG and hydroxychloroquine.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B15I</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B07</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17H</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Traitement</s0>
<s5>07</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Treatment</s0>
<s5>07</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>07</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Voie abord</s0>
<s5>08</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Surgical approach</s0>
<s5>08</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vía abordaje</s0>
<s5>08</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Dermatomyosite</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dermatomyositis</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Dermatomiositis</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Adolescent</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Adolescent</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Adolescente</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Amérique du Nord</s0>
<s2>NG</s2>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>North America</s0>
<s2>NG</s2>
<s5>13</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>America del norte</s0>
<s2>NG</s2>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Enfant</s0>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Child</s0>
<s5>14</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Niño</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Arthrite</s0>
<s5>15</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Arthritis</s0>
<s5>15</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Artritis</s0>
<s5>15</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Rhumatologie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Rheumatology</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Reumatología</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Enquête</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Survey</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Encuesta</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Pédiatrie</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Pediatrics</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Pediatría</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Myosite</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Myositis</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Miositis</s0>
<s5>19</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Amérique</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie autoimmune</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Autoimmune disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad autoinmune</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie de système</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Systemic disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad sistémica</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du muscle strié</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Striated muscle disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Músculo estriado patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie de la peau</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Skin disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Piel patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Pathologie du tissu conjonctif</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Connective tissue disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Tejido conjuntivo patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Immunopathologie</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Immunopathology</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Inmunopatología</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Pathologie du système ostéoarticulaire</s0>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Diseases of the osteoarticular system</s0>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Sistema osteoarticular patología</s0>
<s5>43</s5>
</fC07>
<fN21><s1>291</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0446161 INIST</NO>
<ET>Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey</ET>
<AU>STRINGER (Elizabeth); BOHNSACK (John); BOWYER (Suzanne L.); GRIFFIN (Thomas A.); HUBER (Adam M.); LANG (Bianca); LINDSLEY (Carol B.); OTA (Sylvia); PILKINGTON (Clarissa); REED (Ann M.); SCUCCIMARRI (Rosie); FELDMAN (Brian M.)</AU>
<AF>IWK Health Centre/Halifax, Nova Scotia/Canada; University of Utah School of Medicine/Salt Lake City, Utah/Etats-Unis; Indiana University School of Medicine/Indianapolis, Indiana/Etats-Unis; Cincinnati Children's Hospital/Cincinnati, Ohio/Etats-Unis; University of Kansas Medical Center/Kansas City, Kansas/Etats-Unis; The Hospital for Sick Children/Toronto, Ontario/Canada; Great Ormond Street Hospital for Children/London/Royaume-Uni; Mayo Clinic/Rochester, Minnesota/Etats-Unis; Montreal Children's Hospital/Montreal, Quebec/Canada</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of rheumatology; ISSN 0315-162X; Coden JRHUA9; Canada; Da. 2010; Vol. 37; No. 9; Pp. 1953-1961; Bibl. 43 ref.</SO>
<LA>Anglais</LA>
<EA>Objective. There are a number of different approaches to the initial treatment of juvenile dermatomyositis (JDM). We assessed the therapeutic approaches of North American pediatric rheumatologists to inform future studies of therapy in JDM. Methods. A survey describing clinical cases of JDM was sent to pediatric rheumatologists. The cases described children with varying severity of typical disease, disease with atypical features, or refractory disease. Three open-ended questions were asked following each case: (1) What additional investigations would you order; (2) What medicine(s) would you start (dose, route, frequency, adjustment over time); and (3) What nonmedication treatment(s) would you start. Results. The response rate was 84% (141/167). For typical cases of JDM, regardless of severity, almost all respondents used corticosteroids and another medication, methotrexate (MTX) being the most commonly used. The route and pattern of corticosteroid administration was variable. Intravenous immunoglobulin (IVIG) was used more frequently for more severe disease, for refractory disease, and for prominent cutaneous disease. Hydroxychloroquine was often used in milder cases and cases principally characterized by rash. Cyclophosphamide was reserved for ulcerative disease and JDM complicated by lung disease. Conclusion. For the majority of North American pediatric rheumatologists, corticosteroids and MTX appear to be the standard of care for typical cases of JDM. There is variability, however, in the route of administration of corticosteroids and use of IVIG and hydroxychloroquine.</EA>
<CC>002B15I; 002B07; 002B17H</CC>
<FD>Traitement; Voie abord; Dermatomyosite; Adolescent; Amérique du Nord; Enfant; Arthrite; Rhumatologie; Enquête; Pédiatrie; Myosite</FD>
<FG>Homme; Amérique; Maladie autoimmune; Maladie de système; Pathologie du muscle strié; Pathologie de la peau; Pathologie du tissu conjonctif; Immunopathologie; Pathologie du système ostéoarticulaire</FG>
<ED>Treatment; Surgical approach; Dermatomyositis; Adolescent; North America; Child; Arthritis; Rheumatology; Survey; Pediatrics; Myositis</ED>
<EG>Human; America; Autoimmune disease; Systemic disease; Striated muscle disease; Skin disease; Connective tissue disease; Immunopathology; Diseases of the osteoarticular system</EG>
<SD>Tratamiento; Vía abordaje; Dermatomiositis; Adolescente; America del norte; Niño; Artritis; Reumatología; Encuesta; Pediatría; Miositis</SD>
<LO>INIST-16024.354000194840140270</LO>
<ID>10-0446161</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000016 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000016 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:10-0446161 |texte= Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey }}
This area was generated with Dilib version V0.6.33. |